Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records
- 1 March 2002
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 24 (3) , 378-396
- https://doi.org/10.1016/s0149-2918(02)85040-8
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Hepatocellular Injury in a Patient Receiving PioglitazoneAnnals of Internal Medicine, 2001
- Thiazolidinediones for type 2 diabetesBMJ, 2001
- Nonhypoglycemic Effects of ThiazolidinedionesAnnals of Internal Medicine, 2001
- Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonistsJournal of Clinical Investigation, 2000
- Thiazolidinediones: an updateThe Lancet, 2000
- Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case ReportAnnals of Internal Medicine, 2000
- Medical significance of peroxisome proliferator-activated receptorsThe Lancet, 1999
- An Autopsy Case of Troglitazone-Induced Fulminant HepatitisDiabetes Care, 1998
- Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with TroglitazoneAnnals of Internal Medicine, 1998
- Hepatic Dysfunction Associated with TroglitazoneNew England Journal of Medicine, 1998